Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.953650
Keywords
HTLV 1; TAX; envelope (E); glycoprotein (GP); vaccine; neutralizing abs; cytotoxic T cell
Categories
Funding
- PHS [CA252869, CA255095, CA100730, AI156014]
Ask authors/readers for more resources
HTLV-1 is a global infection with transmission through blood, needles, mother-to-child exposure, and sexual intercourse. Infection is associated with immunosuppression and shorter survival. Few vaccines targeting HTLV-1 proteins have been investigated so far, but new technologies have opened possibilities for renewed research in search of a safe and effective vaccine.
HTLV-1 is a global infection with 5-20 million infected individuals. Although only a minority of infected individuals develop myelopathy, lymphoproliferative malignancy, or inflammatory disorders, infection is associated with immunosuppression and shorter survival. Transmission of HTLV-1 is through contaminated blood or needles, mother-to-child exposure through breast-feeding, and sexual intercourse. HTLV-1 is a delta retrovirus that expresses immunogenic Gag, Envelope, TAX, and Hbz proteins. Neutralizing antibodies have been identified directed against the surface envelope protein, and cytotoxic T-cell epitopes within TAX have been characterized. Thus far, there have been few investigations of vaccines directed against each of these proteins, with limited responses, thus far. However, with new technologies developed in the last few years, a renewed investigation is warranted in search for a safe and effective HTLV-1 vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available